News
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...
Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback